TN SB2097 | 2021-2022 | 112th General Assembly
Status
Spectrum: Partisan Bill (Republican 1-0)
Status: Introduced on January 31 2022 - 25% progression, died in chamber
Action: 2022-02-25 - Withdrawn.
Text: Latest bill text (Draft #1) [PDF]
Status: Introduced on January 31 2022 - 25% progression, died in chamber
Action: 2022-02-25 - Withdrawn.
Text: Latest bill text (Draft #1) [PDF]
Summary
As introduced, requires certain insurers with policies or contracts that provide coverage for Veklury (remdesivir) to also provide coverage for monoclonal antibody infusions and budesonide treatment at a cost to the insured no greater than the cost of Veklury (remdesivir) to the insured on or after July 1, 2022. - Amends TCA Title 8; Title 56 and Title 71.
Title
AN ACT to amend Tennessee Code Annotated, Title 8; Title 56 and Title 71, relative to insurance.
Sponsors
| Sen. Mark Pody [R] |
History
| Date | Chamber | Action |
|---|---|---|
| 2022-02-25 | Senate | Withdrawn. |
| 2022-02-25 | Senate | Recalled from Senate Commerce & Labor Committee |
| 2022-02-03 | Senate | Passed on Second Consideration, refer to Senate Commerce and Labor Committee |
| 2022-02-02 | Senate | Introduced, Passed on First Consideration |
| 2022-01-31 | Senate | Filed for introduction |
Subjects
Tennessee State Sources
| Type | Source |
|---|---|
| Summary | https://wapp.capitol.tn.gov/apps/Billinfo/default.aspx?BillNumber=SB2097&ga=112 |
| Text | https://www.capitol.tn.gov/Bills/112/Bill/SB2097.pdf |
